PDF(Pubmed)
Abstract：
UNASSIGNED: Multiple sclerosis (MS) is a neurodegenerative disease accumulating disabilities over time. However, the mean age of individuals with MS is increasing, consequently elevating their risk of developing comorbidities. Comorbidities\' impact on MS is widely debated. Yet very few countries possess population-based registries, which provide unique opportunities for individual-level data linkage. This study aims to assess acute and chronic comorbidities among elderly patients with MS, comparing them to matched controls. Additionally, this study seeks to investigate the influence of chronic comorbidities on all-cause mortality.
UNASSIGNED: A nationwide register-based study using the Danish Multiple Sclerosis Registry to identify all living patients with MS older than 50 years at the reference date (January 1st, 2022). Patients were matched 1:10 with individuals from the general population. Comprehensive healthcare data within the Danish hospital system were obtained. Chronic comorbidities were classified according to the Charlson Comorbidity Index, while acute comorbidities were based on ICD-10 codes and an \"acute\" admission type. To investigate all-cause mortality, a Cox regression analysis was conducted.
UNASSIGNED: The study encompassed a total of 8,688 individuals with MS, matched with 86,880 controls. The mean age was 63.5 years, with females constituting 68.3%. Individuals with MS exhibited a higher frequency of acute hospitalizations (OR: 2.1, 95% CI: 1.9-2.2), primarily due to various infectious diseases, along with longer median hospital stays (4 vs. 3 days, p < 0.001). When assessed using the Charlson Comorbidity Index, individuals with MS carried a significantly greater burden of chronic comorbidities (p < 0.001). The most prevalent chronic comorbidity among individuals with MS was \"Uncomplicated Diabetes\" (20.1%). Notably, while individuals with MS displayed an overall lower 5-year survival rate, this difference ceased to be statistically significant among those with a high Charlson Comorbidity Index score of ≥4 (p = 0.32).
UNASSIGNED: This study highlights a heightened prevalence of both acute and chronic comorbidities among individuals with MS, with chronic comorbidities significantly increasing the risk of mortality. These findings underscore the critical importance of factoring in comorbidities when devising treatment strategies for individuals living with MS.
UNASSIGNED: A nationwide register-based study using the Danish Multiple Sclerosis Registry to identify all living patients with MS older than 50 years at the reference date (January 1st, 2022). Patients were matched 1:10 with individuals from the general population. Comprehensive healthcare data within the Danish hospital system were obtained. Chronic comorbidities were classified according to the Charlson Comorbidity Index, while acute comorbidities were based on ICD-10 codes and an \"acute\" admission type. To investigate all-cause mortality, a Cox regression analysis was conducted.
UNASSIGNED: The study encompassed a total of 8,688 individuals with MS, matched with 86,880 controls. The mean age was 63.5 years, with females constituting 68.3%. Individuals with MS exhibited a higher frequency of acute hospitalizations (OR: 2.1, 95% CI: 1.9-2.2), primarily due to various infectious diseases, along with longer median hospital stays (4 vs. 3 days, p < 0.001). When assessed using the Charlson Comorbidity Index, individuals with MS carried a significantly greater burden of chronic comorbidities (p < 0.001). The most prevalent chronic comorbidity among individuals with MS was \"Uncomplicated Diabetes\" (20.1%). Notably, while individuals with MS displayed an overall lower 5-year survival rate, this difference ceased to be statistically significant among those with a high Charlson Comorbidity Index score of ≥4 (p = 0.32).
UNASSIGNED: This study highlights a heightened prevalence of both acute and chronic comorbidities among individuals with MS, with chronic comorbidities significantly increasing the risk of mortality. These findings underscore the critical importance of factoring in comorbidities when devising treatment strategies for individuals living with MS.
摘要：
■多发性硬化症（MS）是一种神经退行性疾病，随着时间的推移而积累残疾。然而,MS患者的平均年龄在增加，因此提高了他们发展合并症的风险。合并症对MS的影响受到广泛争论。然而，很少有国家拥有基于人口的登记册，这为个人级别的数据链接提供了独特的机会。本研究旨在评估老年MS患者的急性和慢性合并症。将它们与匹配的控件进行比较。此外,本研究旨在探讨慢性合并症对全因死亡率的影响.
■一项全国性的基于注册的研究，该研究使用丹麦多发性硬化症注册中心，以确定在参考日期（1月1日，2022年）。患者与普通人群中的个体1:10匹配。获得了丹麦医院系统内的全面医疗保健数据。根据Charlson合并症指数对慢性合并症进行分类，而急性合并症基于ICD-10编码和“急性”入院类型。为了调查全因死亡率，进行了Cox回归分析。
■该研究共包括8,688名MS患者，与86,880个对照相匹配。平均年龄为63.5岁,女性占68.3%。MS患者的急性住院频率更高（OR：2.1，95％CI：1.9-2.2），主要是由于各种传染病，以及更长的中位住院时间(4vs.3天,p<0.001)。当使用Charlson合并症指数进行评估时，MS患者的慢性合并症负担显著增加(p<0.001).MS患者中最常见的慢性合并症是“单纯性糖尿病”（20.1％）。值得注意的是,而MS患者的5年生存率总体较低，在Charlson合并症指数高评分≥4的患者中,这一差异不再具有统计学意义(p=0.32).
这项研究强调了MS患者中急性和慢性合并症的患病率增加，慢性合并症显著增加死亡风险。这些发现强调了在为患有MS的个体制定治疗策略时，考虑合并症的重要性。
■一项全国性的基于注册的研究，该研究使用丹麦多发性硬化症注册中心，以确定在参考日期（1月1日，2022年）。患者与普通人群中的个体1:10匹配。获得了丹麦医院系统内的全面医疗保健数据。根据Charlson合并症指数对慢性合并症进行分类，而急性合并症基于ICD-10编码和“急性”入院类型。为了调查全因死亡率，进行了Cox回归分析。
■该研究共包括8,688名MS患者，与86,880个对照相匹配。平均年龄为63.5岁,女性占68.3%。MS患者的急性住院频率更高（OR：2.1，95％CI：1.9-2.2），主要是由于各种传染病，以及更长的中位住院时间(4vs.3天,p<0.001)。当使用Charlson合并症指数进行评估时，MS患者的慢性合并症负担显著增加(p<0.001).MS患者中最常见的慢性合并症是“单纯性糖尿病”（20.1％）。值得注意的是,而MS患者的5年生存率总体较低，在Charlson合并症指数高评分≥4的患者中,这一差异不再具有统计学意义(p=0.32).
这项研究强调了MS患者中急性和慢性合并症的患病率增加，慢性合并症显著增加死亡风险。这些发现强调了在为患有MS的个体制定治疗策略时，考虑合并症的重要性。
